QNCX (Quince Therapeutics) Moat Score: 3/10 (As of Jul. 13, 2026)


QNCX Quince Therapeutics Inc QNCX
21 GF Score
Price $17.48
! 2 Warning Signs
View Full Analysis

What is Quince Therapeutics Moat Score?

Quince Therapeutics QNCX +1.07% 21 Moat Score is 3 as of Jul. 13, 2026. GuruFocus rates QNCX with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 1,396 Biotechnology companies, Quince Therapeutics ranks better than 75.57% on this metric.

Quince Therapeutics has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Quince Therapeutics has No Moat: Quince Therapeutics Inc has limited market share and lacks significant network effects or customer loyalty. While it may have some intellectual property, it does not translate into a strong competitive advantage. Regulatory barriers are not significant enough to provide a moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Quince Therapeutics might have No Moat - Very weak/transient advantages.

Quince Therapeutics  (NAS:QNCX) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Quince Therapeutics Moat Score Related Terms

QNCX vs ATOS, ZIVO, KTTA: Moat Score Comparison

For the Biotechnology subindustry, Quince Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quince Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quince Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Quince Therapeutics's Moat Score falls into.


QNCX
21GF Score
Quince Therapeutics Inc QNCX
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Quince Therapeutics (QNCX) has a Moat Score of 3 as of Jul. 13, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Quince Therapeutics ranks #341 out of 1396 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Quince Therapeutics' Moat Score too high?
Quince Therapeutics' current Moat Score is 3. The Biotechnology industry median Moat Score is 2.00. Quince Therapeutics' value of 3 is 50% above this industry median. Based on the distribution chart, Quince Therapeutics ranks #341 out of 1396 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Quince Therapeutics has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Quince Therapeutics' Moat Score compare to ATOS and ZIVO?
According to the Biotechnology industry distribution chart, Quince Therapeutics ranks #341 out of 1396 companies for Moat Score. This places Quince Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Quince Therapeutics' value of 3 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quince Therapeutics's current Moat Score of 3 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quince Therapeutics's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quince Therapeutics stock overvalued right now?
Quince Therapeutics (QNCX) has a current Moat Score of 3. The current Moat Score is 3 and 50% above the Biotechnology industry median of 2.00. Quince Therapeutics' overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Quince Therapeutics (QNCX), the current Moat Score is 3 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Quince Therapeutics Business Description

Address 611 Gateway Boulevard, Suite 273, South San Francisco, CA, USA, 94080
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.
21GF Score

Get the complete analysis for QNCX

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.48
Price